Skip to the guide Nevada What “specialist” leaves unanswered Words & medicines Start here Words to know Made-to-order medicine Research labels Finding care Care questions Nevada license checks Online visit terms Before a visit Questions to carry Costs & cautions Cost notes Insurance notes Cautions for care Claims to question Notes and sources Words & medicines # What does “research use only” leave out? Treat the phrase as a label to question. It does not answer whether the product is a medicine for your care. ## Read the offer as well as the label FDA is the national agency for medicine reviews. Read “FDA” as “Food and Drug Administration.” Evidence note ### A label is not a shield The letters reviewed through September 26, 2026 contained FDA allegations of unlawful sales under federal law: peptides promoted for human use carried research labels but were unapproved drugs. FDA: concerns about weight-care preparations These letters concern particular firms and describe FDA’s allegations; they are not court judgments. ### What if the page describes treatment? For a peptide offer, federal drug rules look at what the product is meant to do, as checked September 26, 2026. A seller’s promises to treat disease or change how the body works help show that purpose. Keep the product name and the treatment claim together when asking the person caring for you about an offer. ## A product code does not settle approval National Drug Code The government directory uses an identifying number for each listed drug product: its National Drug Code (NDC). Evidence note ### Listed does not mean reviewed A drug code or a directory listing was not evidence of approval, FDA stated at the September 26, 2026 check. FDA: product codes and approval Ask for the product’s approval record, rather than accepting a directory screenshot as the answer. ## Use the exact name when asking Online peptide offers include names such as retatrutide, BPC-157, and ipamorelin. The September 26, 2026 search found no entries for these names in FDA’s public records of applications for drug approval. The search showed no FDA-approved US product for those names. A missing entry is not a refusal of approval. The search also did not tell us whether each substance could legally be made into a medicine to order. Ask about that separate question for the exact substance. Evidence note ### A specific federal position Cagrilintide is another substance named in FDA’s warning about unapproved drugs. Federal law did not permit compounding with retatrutide or cagrilintide, according to FDA’s position checked September 26, 2026. FDA: concerns about weight-care preparations ### What can I ask instead? Ask which approved treatments may help with your health problem and what studies show about them. Ask what other causes of your problem the person caring for you would check for. Check the claims in an offer These notes serve as a care guide. This site neither operates as a clinic nor sells medicine. Return to the start Check a source Carry your questions Read as text